Eli Lilly and Company
PARATHYROID HORMONE-ANTI-RANKL ANTIBODY FUSION COMPOUNDS

Abstract:

Fusion compounds and methods of using same are provided which bind and neutralize human receptor activator of nuclear factor kappa-B ligand and are agonistic to parathyroid hormone receptor 1 signaling, said compounds are useful as agents for bone healing or treating conditions associated with bone mass loss or degeneration including treating osteoporosis.